CBD Life Sciences Developing Bladder Control Supplement
LBC Bioscience Inc., a wholly owned subsidiary of CBD Life Sciences, (OTCPK:CBDL) is working towards launching a bladder control supplement.
The Green Organic Dutchman Launches Four New Cannabis Products
The Green Organic Dutchman Holdings Ltd. (OTCQX: TGODF) (CSE:TGOD), announced new fall 2022 SKU launches.
With record yields and increased growing capacity, the organization will now offer products in additional size options:
Canaccord Genuity Upgrades Aurora Cannabis to Hold, Lowers Price Target to C$2
Canaccord Genuity analyst Matt Bottomley upgrades Aurora Cannabis (TSX:ACB) from Sell to Hold and lowers the price target from C$2.5 to C$2.
IGC Announces Issuance Of Second Patent For The Treatment Of Alzheimer’s Using THC
India Globalization Capital, Inc. (AMEX:IGC) announced that the United States Patent and Trademark Office issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease.”
Cantor Fitzgerald Maintains Overweight on Aurora Cannabis, Lowers Price Target to C$3
Cantor Fitzgerald analyst Pablo Zuanic maintains Aurora Cannabis (TSX:ACB) with a Overweight and lowers the price target from C$3.8 to C$3.
Aurora Cannabis Reports 2022 Q4 Earnings: Revenue Flat Sequentially At C$50.2M, CEO Optimistic
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a Canadian global company in the cannabis industry, serving both the medical and consumer markets; recently announced its financial and operational results for the fourth quarter a
Seelos Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS:
Allied (OTC:ALID) shares closed up 7.83% at $0.62
Cannabis Stock Gainers And Losers From September 20, 2022
GAINERS:
Item 9 Labs (OTC:INLB) shares closed up 8.89% at $0.49
FDA Says No Way To Food Companies Wanting To Get On The CBD Gravy Train
As several major food makers are champing at the bit to cash in on the CBD food and drinks craze, it seems the FDA is still not down with the program.
Clinical Research Comparing Effects Of Novel MDMA Matches In Healthy Patients Begins In Switzerland
The clinical trial investigating the effects of MDMA analogs in healthy volunteers led by PI Prof. Dr. Matthias Liechti and supported by psychedelics biotech company Mind Medicine Inc. (NASDAQ: MNMD) has begun patient dosing.